ELIXER raises equity at £2.2M valuation ahead of August 2026 UK launch
What's the deal? ELIXERDealroom has a profile for this one. Try Dealroom →, a UK health and wellness company based in Essex, has completed an early-stage equity investment through the issue of new ordinary shares, implying a pre-money valuation of about £2.2 million. The transaction will be recorded in the company's SH01 share allotment filing with Companies House.
Why now? The raise comes as ELIXER prepares to launch ELIXER ONE, a new flagship product, at the end of August 2026. The company is also in talks over up to £100,000 in additional private growth capital.
What's the endgame? ELIXER ONE targets adults over 30 with what the company calls a simpler approach to supplementation, an audience it plans to make central to future development. It will launch alongside ELIXER's existing NMN and creatine products, backed by redesigned digital platforms and a dedicated e-commerce experience.
Founder Rowan Bradley said the company intends to stay lean and deploy capital selectively. "The investment gives us the opportunity to properly test what we've built without dramatically increasing our fixed costs," he said, adding that the next stage is "about proving that commercially."
The signal: ELIXER is manufacturing in the UK at a BRCGS AA+ certified facility and has tied its brand to sport, renaming Wivenhoe Town Football ClubDealroom has a profile for this one. Try Dealroom →'s ground the ELIXER Arena under a sponsorship deal. The moves point to a modest, UK-anchored supplements brand shifting from build mode to commercial proof.
Read more: Business Insider
Image credit: formulatehealth
